Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe

AIDS

Volumn 21, Issue 12, 2007, Pages 1515-1523

  Brown, Joelle M ^a   Wald, Anna ^d   Hubbard, Alan ^c   Rungruengthanakit, Kittipong ^g   Chipato, Tsungai ^h   Rugpao, Sungwal ^g   Mmiro, Francis ^f   Celentano, David D ⁱ   Salata, Robert S ^j   Morrison, Charles S ^k   Richardson, Barbra A ^e   Padian, Nancy S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f MAKERERE UNIVERSITY   (Uganda)

^g CHIANG MAI UNIVERSITY   (Thailand)

^h UNIVERSITY OF ZIMBABWE   (Zimbabwe)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^j CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Clinical Research Department   (United States)

more..

Author keywords

Africa; Herpes simplex virus 2; HIV; Marginal structural models; Population attributable risk; Women

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROPREVALENCE; SEXUAL BEHAVIOR; UGANDA; ZIMBABWE;

ADOLESCENT; ADULT; EPIDEMIOLOGIC METHODS; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HUMANS; SEXUAL BEHAVIOR; UGANDA; ZIMBABWE;

EID: 34447568145     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282004929     Document Type: Article

References (48)

1. Behets FM, Brathwaite AR, Hylton-Kong T, Chen CY, Hoffman I, Weiss JB, et al. Genital ulcers: etiology, clinical diagnosis, and associated human immunodeficiency virus infection in Kingston, Jamaica. Clin Infect Dis 1999; 28:1086-1090.
2. Beyrer C, Jitwatcharanan K, Natpratan C, Kaewvichit R, Nelson KE, Chen CY, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243-246.
3. Chen CY, Ballard RC, Beck-Sague CM, Dangor Y, Radebe F, Schmid S, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000; 27:21-29.
4. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
5. Limpakarnjanarat K, Mastro TD, Saisorn S, Uthaivoravit W, Kaewkungwal J, Korattana S, et al. HIV-1 and other sexually transmitted infections in a cohort of female sex workers in Chiang Rai, Thailand. Sex Transm Infect 1999; 75:30-35.
6. Morse SA, Trees DL, Htun Y, Radebe F, Orle KA, Dangor Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997; 175:583-589.
7. WHO/UN AIDS. Herpes Simplex Virus Type 2: Programmatic and Research Priorities in Developing Countries. Geneva: World health Organization; 2001.
8. Cunningham AL, Nelson PA, Fathman CG, Merigan TC. Interferon gamma production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. J Gen Virol 1985; 66 (Pt 2):249-258.
9. Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R, et al. Antigenic specificities of human CD4R T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994; 68:2803-2810.
10. Corey L, Wald A. Sexually Transmitted Diseases. 3rd edn. New York: McGraw-Hill; 1999.
11. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
12. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
13. Nicolosi A, Musicco M, Saracco A, Lazzarin A. Risk factors for woman-to-man sexual transmission of the human immunodeficiency virus. Italian Study Group on HIV Heterosexual Transmission. J Acquir Immune Defic Syndr 1994; 7:296-300.
14. Carpenter LM, Kamali A, Ruberantwari A, Malamba SS, Whitworth JA. Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. AIDS 1999; 13:1083-1089.
15. del Mar Pujades Rodriguez M, Obasi A, Mosha F, Todd J, Brown D, Changalucha J, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002; 16:451-462.
16. Morrison C, Richardon B, Mmiro F, Chipato T, Celentano D, Luoto J, et al. Hormonal contraception and risk of acquiring HIV infection. AIDS 2007; 21:85-95.
17. Hogrefe W, Su X, Song J, Ashley R, Kong L. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition. J Clin Microbiol 2002; 40:3635-3640.
18. Laeyendecker O, Henson C, Gray RH, Nguyen RH, Horne BJ, Wawer MJ, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004; 42:1794-1796.
19. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
20. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131:14-20.
21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
22. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
23. van der Laan M, Robins J. Unified Methods for Censored Longitudinal Data and Causality. New York: Springer; 2003.
24. Robins JM. Association, causation, and marginal structural models. Synthese 1999; 121:151-179.
25. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
26. Fisher R. Statistical Methods for Research Workers. 13th edn. Edinburgh: Oliver & Boyd; 1932.
27. Hubbard A, van der Laan M. UC Berkeley Division of Biostatistics Working Paper Series 151: Population Intervention Models in Causal Inference. Berkeley, CA: University of California Press; 2005.
28. McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999; 180:1459-1465.
29. de Vincenzi I. A longitudinal study of human immunodefi-ciency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331:341-346.
30. Cayley WE Jr. Effectiveness of condoms in reducing heterosexual transmission of HIV. Am Fam Physician 2004; 70:1268-1269.
31. Wald A, Langenberg AG, Krantz E, Douglas JM Jr, Handsfield HH, DiCarlo RP, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707-713.
32. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-3106.
33. Gottlieb SL, Douglas JM Jr, Foster M, Schmid DS, Newman DR, Baron AE, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004; 190:1059-1067.
34. Corey L, Ashley R. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes 2004; 11:170A-174A.
35. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006; 194:42-52.
36. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004; 11 (Suppl 3):161A-169A.
37. Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004; 80:24-29.
38. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS1265 Trial. PLoS Med 2005; 2911:e298.
39. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006; 439:89-94.
40. Johnson DC. Silencing herpes simplex virus with a vaginal microbicide. N Engl J Med 2006; 354:970-971.
41. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006; 193:27-35.
42. Anderson RA, Feathergill KA, Diao XH, Cooper MD, Kirkpatrick R, Herold BC, et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl 2002; 23:426-438.
43. Carlucci MJ, Scolaro LA, Noseda MD, Cerezo AS, Damonte EB. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. Antiviral Res 2004; 64:137-141.
44. Bernstein DI, Stanberry LR, Sacks S, AyisiNK, GongYH, Ireland J, et al. Evaluations of unformulated and formulated dendrimer-based microbicide candidates inmouse and guinea pigmodels of genital herpes. Antimicrob Agents Chemother 2003; 47:3784-3788.
45. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001; 28:417-423.
46. Maguire RA, Bergman N, Phillips DM. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 2001; 28:259-265.
47. Piret J, Lamontagne J, Bestman-Smith J, Roy S, Gourde P, Desormeaux A, et al. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J Clin Microbiol 2000; 38:110-119.
48. Zaneveld LJ, Waller DP, Anderson RA, Chany C 2nd, Rencher WF, Feathergill K, et al. Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly(sodium 4-styrenesulfonate). Biol Reprod 2002; 66:886-894.